Jeffrey A. Meckler - 27 Jul 2025 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: INDP
Reported as of: 27 Jul 2025
Net transaction value: +$151,137
SEC form: 4
Accepted by SEC: 29 Jul 2025, 16:15:27 UTC
Prior SEC filing: 16 May 2025
Next SEC filing: 29 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Meckler

Key filing fact

Jeffrey A. Meckler filed Form 4 for Indaptus Therapeutics, Inc. (INDP) on 29 Jul 2025.

Key facts

This page summarizes Jeffrey A. Meckler's Form 4 filing for Indaptus Therapeutics, Inc. (INDP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jul 2025, 16:15.

Change

Previous filing in this sequence was filed on 16 May 2025.
Current net transaction value: +$151,137.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001506916 Primary reporting owner

Meckler Jeffrey A

Relationship: Chief Executive Officer, Director
Address: C/O INDAPTUS THERAPEUTICS, INC, 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK
Signature: /s/ Jeffrey Meckler
Signature date: 29 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDP transaction

Common Stock

Award

Transaction value: $50,379
Shares: +6,068
Change %: +84%
Price: $8.30
Shares after: 13,312
Date: 27 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDP transaction Derivative

Common Stock Warrants

Award

Transaction value: $100,758
Shares: +12,136
Change %: +267%
Price: $8.30
Shares after: 16,688
Date: 27 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,136
Exercise price: $8.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025.

SEC remarks

On June 26, 2025, the Company implemented a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.